EntreMed issued patent for 2-methoxyestradiol analogs through 2020

By Elaine Rigoli

Tampa, Fla., Feb. 14 - EntreMed, Inc. announced Tuesday the issuance of U.S. Patent No. 6,995,278 covering analogs of its lead compound, 2-methoxyestradiol (2ME2 or Panzem).

The patent grants EntreMed composition-of-matter intellectual property protection through 2020 for analogs of 2ME2 in oncology and a broad range of non-oncology indications, including inflammatory and immune disorders, rheumatoid arthritis, and other diseases characterized by abnormal cell division. The patent covers novel antiangiogenic compositions.

Panzem, an antimitotic cancer drug that binds to tubulin and works through multiple cellular pathways, is currently in clinical trials for cancer and preclinical development for inflammatory disorders.

Panzem can attack tumors on multiple fronts - directly by disrupting microtubules, an intracellular matrix necessary for the rapid division of cancer cells (mitosis), by inducing programmed cell death (apoptosis), and by blocking blood vessels that feed tumors (angiogenesis inhibition), according to a company release. Analogs of 2ME2 have been developed by EntreMed to decrease metabolism while retaining their antiproliferative and antiangiogenic properties.

Based in Rockville, Md., EntreMed is a clinical-stage pharmaceutical company developing therapeutic candidates primarily for the treatment of cancer and inflammation.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.